Advanced Imaging and Receipt of Guideline Concordant Care in Women with Early Stage Breast Cancer
Table 4
Multivariable results by guideline for the association between receipt of advanced imaging and receipt of guideline concordant care for women with early stage breast cancer controlling for confounding variables.
Guideline
Odds ratio
95% confidence interval
p value
Radiation following Lumpectomy ( = 4,085)
Mammogram/ultrasound
Ref.
—
—
Breast MRI
1.55
(1.08, 2.26)
0.02
CT, PET, and PET/CT
1.02
(0.67, 1.63)
0.92
Radiation following Mastectomy ()
Mammogram/ultrasound
Ref.
—
—
Breast MRI
0.53
(0.19, 1.53)
0.24
CT, PET, and PET/CT
1.08
(0.39, 3.17)
0.88
Chemotherapy for ER+ Disease = 1,453
Mammogram/ultrasound
Ref.
—
—
Breast MRI
1.37
(0.96, 1.96)
0.09
CT, PET, and PET/CT
1.74
(1.17, 2.59)
0.01
Chemotherapy for ER− Disease ()
Mammogram/ultrasound
Ref.
—
—
Breast MRI
1.07
(0.58, 2.00)
0.83
CT, PET, and PET/CT
1.61
(0.89, 2.97)
0.12
ER+: estrogen receptor positive. ER−: estrogen receptor negative. MRI: magnetic resonance imaging. CT: computed tomography. PET: positron emission tomography. Confounding variables included age, race, residence, plan type, income, year, comorbidity, and time from diagnosis to definitive surgery.
